GLP-1 Agonist Phase III

Retatrutide

Also known as: LY3437943, Reta

An investigational triple agonist targeting GIP, GLP-1, and glucagon receptors — produced record-breaking 24.2% weight loss in Phase 2 trials.

Popularity A+
Class Triple GIP/GLP-1/Glucagon Receptor Agonist
Half-Life ~6 days
Form Lyophilized powder (research), Pre-filled pen (clinical)
Jump to Dosing ↓
Retatrutide
Research-Backed User Reports Sourced Updated Mar 2026
// Overview

What is Retatrutide?

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly that targets GIP, GLP-1, and glucagon receptors simultaneously. It represents the next evolution beyond dual agonists like tirzepatide, adding glucagon receptor activity to further enhance metabolic effects.

In the Phase 2 trial published in the New England Journal of Medicine, retatrutide produced up to 24.2% body weight loss at the highest dose over 48 weeks — the largest weight reduction ever reported for any anti-obesity medication in a clinical trial. The triple-agonist approach addresses obesity from three distinct hormonal pathways.

The addition of glucagon receptor agonism increases energy expenditure and hepatic lipid oxidation, complementing the appetite-suppressing effects of GIP and GLP-1 activation. This mechanism also showed remarkable effects on liver fat reduction, with some patients achieving complete resolution of fatty liver disease.

Found this helpful?

Join our newsletter for compound breakdowns, dosing protocols, and research updates.

Free forever. No spam. Unsubscribe anytime.

// How It Works

How Retatrutide Works

Retatrutide activates three metabolic hormone receptors simultaneously:

  1. GLP-1 receptor — Suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the primary weight loss mechanism shared with semaglutide.
  2. GIP receptor — Amplifies insulin response, improves lipid metabolism, and may reduce the nausea associated with GLP-1 activation alone.
  3. Glucagon receptor — The novel third target. Increases hepatic fat oxidation, raises energy expenditure (thermogenesis), and promotes lipolysis. This mechanism drives the dramatic liver fat reduction seen in trials.

The triple-agonist approach produces greater weight loss and metabolic improvement than dual (tirzepatide) or single (semaglutide) agonists.

// Dosage Protocols

Dosage Information (User-Reported)

Disclaimer: Dosage information is compiled from user reports and published research. This is not medical advice. Consult a healthcare professional before use.
Level Dose Frequency Duration
Starter 0.5 mg Once weekly 4 weeks
Titration 1 2 mg Once weekly 4 weeks
Titration 2 4 mg Once weekly 4 weeks
Therapeutic Low 8 mg Once weekly Ongoing
Therapeutic High 12 mg Once weekly Ongoing

What to Expect

Week 1-4

Appetite reduction begins at low titration doses. GI effects similar to other GLP-1 drugs. Some users report increased body temperature from glucagon activity.

Week 5-12

Dramatic appetite suppression. Faster weight loss trajectory than semaglutide or tirzepatide at equivalent timepoints. Energy expenditure feels elevated.

Month 3-6

Substantial body recomposition. Users report 15-20%+ total weight loss. Liver enzyme normalization in those with elevated baselines.

Month 6-12

Weight loss continues toward 20-25% of starting body weight. Metabolic panels show broad improvement across glucose, lipids, and liver markers.

Common Stacks

BPC-157

GI Support

Helps manage nausea and gastric slowing from triple-agonist activity

L-Carnitine

Fat Metabolism

Supports increased fatty acid oxidation driven by glucagon receptor activation

Electrolytes / Magnesium

Hydration Support

Compensates for increased water loss and mineral depletion during rapid weight reduction

// Preparation

Reconstitution & Storage

Research-grade: Reconstitute with bacteriostatic water. Add water slowly, do not shake. Swirl gently until dissolved. Refrigerate and use within 21 days.

Storage: Refrigerate 2-8°C. Protect from light.
// Safety Profile

Side Effects & Safety

Potential Side Effects

  • ! Nausea (most common during titration)
  • ! Diarrhea
  • ! Vomiting
  • ! Decreased appetite
  • ! Constipation
  • ! Increased heart rate
  • ! Injection site reactions
  • ! Elevated body temperature (glucagon effect)
  • ! Gallbladder events with rapid weight loss

Contraindications

  • ⚠ Personal or family history of medullary thyroid carcinoma
  • ⚠ MEN 2 syndrome
  • ⚠ Pregnancy or breastfeeding
  • ⚠ Active pancreatitis
  • ⚠ Severe hepatic or renal impairment

Legal & Regulatory Status

Investigational — not yet FDA-approved. Currently in Phase 3 clinical trials (TRIUMPH program) by Eli Lilly. Research-grade retatrutide available from select peptide vendors for research purposes only.

// Research

Published Research

// Related Compounds

Other GLP-1 Agonist Guides

Selank peptide nasal spray used for anxiolytic and nootropic research

Selank

A clinically approved anxiolytic peptide offering benzodiazepine-level anxiety relief without sedation, addiction, or cognitive impairment — plus immune…

Read Guide →
Athome blood test kit with fingerprick lancet and collection card for biomarke

Thymosin Alpha 1

A thymic peptide approved in 35+ countries that restores and enhances adaptive immunity — T-cell maturation, antiviral defense,…

Read Guide →
Highresolution illustration of neural pathways lighting up during cognitive enh

VIP

A master regulatory neuropeptide with broad anti-inflammatory, vasodilatory, and neuroprotective effects — critical in mold illness (CIRS) treatment…

Read Guide →

Stay informed on Retatrutide.

New research, dosage updates, and protocol breakdowns. Straight to your inbox.

Free forever. No spam. Unsubscribe anytime.

This content is for informational and educational purposes only. Retatrutide is sold for research purposes. Never Natty does not condone or encourage the use of any substance in violation of any laws. Consult a healthcare professional before using any compound discussed on this site.